GlassScriptPhysician profile
Tarun Shah
NPI 1053385484
$5,577.58
in general payments reported to CMS, 2019-2025
24 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $539 · 2021: $335 · 2022: $581 · 2023: $1,379 · 2024: $911 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.46 |
| Education | $228.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,470.23 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,089.99 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $541.09 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $504.28 | 2019-2025 | Dupixent |
| Optinose US, INC. | $423.67 | 2019-2024 | |
| Boston Scientific Corporation | $203.51 | 2019-2020 | |
| Genentech USA, INC. | $199.30 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $135.12 | 2025 | Neffy |
| Amarin Pharma, INC. | $127.45 | 2019 | |
| Incyte Corporation | $124.99 | 2025 | Opzelura |
| Silk Road Medical, INC. | $122.03 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Becton, Dickinson and Company | $120.81 | 2024 | Phasix Mesh |
| Grifols USA, LLC | $73.46 | 2021-2023 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $69.27 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $60.89 | 2023-2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $55.49 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.24 | 2021-2024 | Entyvio |
| Aimmune Therapeutics, INC. | $48.87 | 2022 | |
| Kaleo, INC. | $27.48 | 2021-2022 | |
| Amgen INC. | $16.67 | 2023 | Tezspire |
| Pfizer INC. | $15.83 | 2023 | |
| Merck Sharp & Dohme LLC | $14.06 | 2023 | |
| Circassia INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.